Login to Your Account



Other News To Note


Wednesday, May 2, 2012
• Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said two leading health insurers in Switzerland agreed to fully reimburse the cost of Scenesse (afamelanotide 16-mg implant) for erythropoietic protoporphyria, a rare disease characterized by severe phototoxicity.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription